Additional Resources

New data regarding the prevention, diagnosis, and management of COVID-19 are emerging daily. Please see the list of COVID-19 resources for healthcare professionals provided below for additional up-to-date and comprehensive information.

Resources CDC, HHS, NIH, and WHO

US Department of Health and Human Services (HHS). Find ways to prevent, treat or help fight COVID-19. https://combatcovid.hhs.gov/

National Institutes of Health (NIH). COVID-19 Treatment Guidelines. https://covid19treatmentguidelines.nih.gov/introduction/

Centers for Disease Control and Prevention (CDC). Evaluating and Testing Persons for Coronavirus Disease 2019 (COVID-19). https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html

CDC. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html

NIH. COVID-19 Treatment Guidelines. https://covid19treatmentguidelines.nih.gov/introduction/

CDC. Information for Healthcare Professionals about Coronavirus (COVID-19). https://www.cdc.gov/coronavirus/2019-nCoV/hcp/index.html

World Health Organization (WHO). Country & Technical Guidance – Coronavirus disease (COVID-19). https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance

Additional Guidance on the Management of Patients with COVID-19.

Society of Critical Care Medicine. Surviving Sepsis Campaign: COVID-19 Guidelines. https://www.sccm.org/SurvivingSepsisCampaign/Guidelines/COVID-19

Infectious Disease Society of America (IDSA). COVID-19 Resource Center. https://www.idsociety.org/public-health/COVID-19-Resource-Center/

IDSA. Infectious Diseases Society of America Guidelines on Infection Prevention in Patients with Suspected or Known COVID-19. https://www.idsociety.org/practice-guideline/covid-19-guideline-infection-prevention/

Recommendations on the Management of Special Populations During the COVID-19 Pandemic.

Al-Shamsi HO, Alhazzani W, Alhuraiji A, et al. A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: an international collaborative group. Oncologist. 2020. https://doi.org/10.1634/theoncologist.2020-0213

American College of Surgeons (ACS). Recommendations for prioritization, treatment and triage of breast cancer patients during the COVID-19 pandemic. Available at https://www.facs.org/quality-programs/cancer/executive-summary

American Society of Clinical Oncology (ASCO). COVID-19 Patient Care Information. https://www.asco.org/asco-coronavirus-information/care-individuals-cancer-during-covid-19

Centers for Disease Control and Prevention (CDC). Considerations for Inpatient Obstetric Healthcare Settings. https://www.cdc.gov/coronavirus/2019-ncov/hcp/inpatient-obstetric-healthcare-guidance.html

American College of Obstetricians and Gynecologists (ACOG). Novel Coronavirus 2019 (COVID-19). https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/03/novel-coronavirus-2019

Supporting Patient Journeys Through Resources and Tools to Promote Positive Patient Outcomes in Care

National Infusion Center Association. COVID-19 Antibody Therapies Resource Center. https://infusioncenter.org/infusion_resources/covid-19-antibody-treatment-resource-center/

CombatCOVID.hhs.gov. Monoclonal Antibodies for High-Risk COVID-19 Positive Patients. https://combatcovid.hhs.gov/i-have-covid-19-now/monoclonal-antibodies-high-risk-covid-19-positive-patients?gclid=EAIaIQobChMI4r-5loX27gIVCaiGCh3AQgwgEAAYASAAEgI76fD_BwE

Joost Wiersinga W, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA. 2020;10.1001/jama.2020.12839. https://pubmed.ncbi.nlm.nih.gov/32648899/

Guan WJ, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-1720. https://pubmed.ncbi.nlm.nih.gov/32109013/

Rothan HA, et al. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. https://pubmed.ncbi.nlm.nih.gov/32113704/

Lechien JR, et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. [published online ahead of print, 2020 Apr 30]. J Intern Med. 2020; 10.1111/joim.13089. https://pubmed.ncbi.nlm.nih.gov/32352202/

Wang W, et al. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol. 2020;92:441-447. https://pubmed.ncbi.nlm.nih.gov/31994742/

Wu Z, et al. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239-1242. https://jamanetwork.com/journals/jama/fullarticle/2762130

Richardson S, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020 May 26;323:2052–2059. https://pubmed.ncbi.nlm.nih.gov/32320003/

Docherty AB, et al. Features of 20,133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study. BMJ. 2020;369:m1985. https://www.bmj.com/content/369/bmj.m1985

Yuan X, et al. Changes of hematological and immunological parameters in COVID-19 patients. [published online ahead of print, 2020 Jul 12]. Int J Hematol. 2020;1-7. https://pubmed.ncbi.nlm.nih.gov/32656638/

Bhimraj A, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. IDSA Guidelines. V2.1.0. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/

Alhazzani W, et al. Surviving Sepsis Campaign: Guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med. 2020;46:854-887. https://pubmed.ncbi.nlm.nih.gov/32222812/

World Health Organization (WHO). Clinical management of COVID-19. Interim Guidance. 2020 May 27. https://www.who.int/publications/i/item/clinical-management-of-covid-19

National Institutes of Health (NIH). COVID-19 Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/

Beigel JH, et al. Remdesivir for the treatment of COVID-19 – Final Report. N Engl J Med. 2020;383:1813-1826. https://www.nejm.org/doi/full/10.1056/NEJMoa2007764

Spinner CD, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324:1048-1057. https://jamanetwork.com/journals/jama/fullarticle/2769871

Horby P, et al. Dexamethasone in hospitalized patients with COVID-19 – preliminary report. N Engl J Med. 2020;Epub ahead of print. https://pubmed.ncbi.nlm.nih.gov/32678530/

Siddiqi HK, et al. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39:405-407. https://www.jhltonline.org/article/S1053-2498(20)31473-X/fulltext

Li L, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial. [published online ahead of print, 2020 Jun 3].JAMA. 2020;e2010044. https://pubmed.ncbi.nlm.nih.gov/32492084/

Kalil AC, et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med. 2020;Epub ahead of print. https://www.nejm.org/doi/full/10.1056/NEJMoa2031994

Baum A, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369:1014-1018. https://pubmed.ncbi.nlm.nih.gov/32540904/

Gandhi RT, et al. Mild or moderate COVID-19. N Engl J Med. 2020;383:1757-1766. https://pubmed.ncbi.nlm.nih.gov/32329974/

Docherty AB, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985. https://pubmed.ncbi.nlm.nih.gov/32444460/

Simonovich VA, et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N Engl J Med. 2020;Epub ahead of print. https://pubmed.ncbi.nlm.nih.gov/33232588/

Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Baricitinib. https://www.fda.gov/media/143823/download

Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Bamlanivimab. http://pi.lilly.com/eua/bamlanivimab-eua-factsheet-hcp.pdf

Fact Sheet for Health Providers Emergency Use Authorization (EUA) of Bamlanivimab and Etesevimab. https://www.fda.gov/media/145802/download

Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Casirivimab and Imdevimab. https://www.fda.gov/media/143892/download

Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of COVID-19 Convalescent Plasma for Treatment of Hospitalized Patients with COVID-19. https://www.fda.gov/media/141478/download

Weinreich DM, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with COVID-29. N Engl J Med. 2020;Epub ahead of print. https://www.nejm.org/doi/pdf/10.1056/NEJMoa2035002

Gottlieb RL, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325:632-644. https://jamanetwork.com/journals/jama/fullarticle/2775647

Chen P, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N Engl J Med. 2020;Epub ahead of print. https://www.nejm.org/doi/full/10.1056/NEJMoa2029849

ACTIV-3/TICO LY-CoV555 Study Group. A neutralizing monoclonal antibody for hospitalized patients with COVID-19. N Engl J Med. 2020;Epub ahead of print. https://www.nejm.org/doi/full/10.1056/NEJMoa2033130

Hansen J, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020;369:1010-1014. https://science.sciencemag.org/content/369/6506/1010

Callaway E. The coronavirus is mutating – does it matter? Nature. 2020;585:174-177. https://www.nature.com/articles/d41586-020-02544-6

Menu

Updates in the Treatment and Prevention of COVID-19​

Molnupiravir, an Oral Antiviral, Reduced the Risk of Hospitalization or Death in Patients with Mild-to-Moderate COVID-19

Molnupiravir, an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death by 50% in an interim analysis of the phase 3 MOVe-OUT trial. The planned analysis evaluated data from 775 at-risk, non-hospitalized adult patients with mild-to-moderate COVID-19. All patients enrolled had at least one risk factor associated with poor COVID-19 outcomes and were randomized within 5 days of symptom onset. At day 29, 7.3% of patients who received molnupiravir were either hospitalized or died, compared with 14.1% of placebo-treated patients (P= .0012). No deaths were reported in patients receiving molnupiravir, compared with 8 deaths in patients who received placebo. The incidence of any adverse event was comparable in the molnupiravir and placebo groups (35% and 40%, respectively). Discontinuation due to adverse events was lower with molnupiravir (1.3%) versus placebo (3.4%).

Reference:

https://www.contagionlive.com/view/molnupiravir-could-become-first-authorized-covid-19-pill